Rhythm Pharmaceuticals, Inc.
RYTMNASDAQHealthcare● Active
$85.93
$-0.48(-0.55%)
Market Cap$5.9B
P/E Ratio—
52W High$122.2
52W Low$60.7
Rhythm Pharmaceuticals, Inc. (RYTM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RYTM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.83
Est. -$0.86 · +3.5%
Revenue
$0.06B
Est. $0.06B · +7.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
RYTM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.82 | — | — | — | $0.07B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.86 | -$0.83 | +3.5% | $0.06B | $0.06B | +7.8% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.79 | -$0.73 | +7.6% | $0.06B | $0.06B | +1.9% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.72 | -$0.82 | -13.9% | $0.05B | $0.06B | -8.4% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.66 | -$0.75 | -13.6% | $0.05B | $0.05B | -5.5% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.69 | -$0.81 | -17.4% | $0.03B | $0.04B | -24.4% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.69 | -$0.72 | -4.3% | $0.04B | $0.04B | +8.7% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.80 | -$0.73 | +8.8% | $0.03B | $0.04B | -7.5% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.82
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.83
EPS Est.
-$0.86
EPS Surpr.
+3.5%
Revenue
$0.06B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.73
EPS Est.
-$0.79
EPS Surpr.
+7.6%
Revenue
$0.06B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.82
EPS Est.
-$0.72
EPS Surpr.
-13.9%
Revenue
$0.05B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.75
EPS Est.
-$0.66
EPS Surpr.
-13.6%
Revenue
$0.05B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.81
EPS Est.
-$0.69
EPS Surpr.
-17.4%
Revenue
$0.03B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.72
EPS Est.
-$0.69
EPS Surpr.
-4.3%
Revenue
$0.04B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.73
EPS Est.
-$0.80
EPS Surpr.
+8.8%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.20 | $0.22 | $0.24 | 2 |
| Q3 FY2027 | $-0.04 | $-0.04 | $-0.04 | 2 |
| Q2 FY2027 | $-0.35 | $-0.33 | $-0.30 | 2 |
| Q1 FY2027 | $-0.71 | $-0.66 | $-0.60 | 3 |
| Q4 FY2026 | $-0.78 | $-0.72 | $-0.66 | 3 |
| Q3 FY2026 | $-0.80 | $-0.78 | $-0.76 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2027 | $0.1B | $0.1B | $0.2B | 5 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 8 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +3.5% | $85.58 | $92.31 | +7.86% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +7.6% | $99.15 | $98.07 | -1.09% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -13.9% | $113.74 | $104.99 | -7.69% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -13.6% | $90.24 | $88.57 | -1.85% |
| ▼ Q2 FY2025 | May 7, 2025 | -17.4% | $62.71 | $64.63 | +3.06% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -4.3% | $51.03 | $53.32 | +4.49% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +8.8% | $52.99 | $56.25 | +6.15% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +21.4% | $44.03 | $44.04 | +0.02% |
Q2 FY2026+7.86%
Report Date
May 5, 2026
EPS Beat/Miss
+3.5%
Price Before
$85.58
Price After
$92.31
Q1 FY2026-1.09%
Report Date
Feb 26, 2026
EPS Beat/Miss
+7.6%
Price Before
$99.15
Price After
$98.07
Q4 FY2025-7.69%
Report Date
Nov 4, 2025
EPS Beat/Miss
-13.9%
Price Before
$113.74
Price After
$104.99
Q3 FY2025-1.85%
Report Date
Aug 5, 2025
EPS Beat/Miss
-13.6%
Price Before
$90.24
Price After
$88.57
Q2 FY2025+3.06%
Report Date
May 7, 2025
EPS Beat/Miss
-17.4%
Price Before
$62.71
Price After
$64.63
Q1 FY2025+4.49%
Report Date
Feb 26, 2025
EPS Beat/Miss
-4.3%
Price Before
$51.03
Price After
$53.32
Q4 FY2024+6.15%
Report Date
Nov 5, 2024
EPS Beat/Miss
+8.8%
Price Before
$52.99
Price After
$56.25
Q3 FY2024+0.02%
Report Date
Aug 6, 2024
EPS Beat/Miss
+21.4%
Price Before
$44.03
Price After
$44.04
Avg Beat Reaction+3.24%
Avg Miss Reaction-0.50%
Beat Rate4 / 8 quarters
Largest Move+7.86% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RYTM ends December
Rhythm Pharmaceuticals, Inc. (RYTM) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.83 — beating the analyst consensus of $-0.86 by +3.5%. RYTM has beaten EPS estimates for 2 consecutive quarters. The next RYTM earnings date is expected around September 1, 2026.
Each quarter, investors track RYTM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RYTM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RYTM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RYTM earnings · 5 questionsRhythm Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RYTM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RYTM historically reports after market close (AMC).
RYTM earnings datewhen is RYTM earningsRYTM next earnings datewhen does RYTM report earningsRYTM earnings calendar
▸ Source: FMP · Rhythm Pharmaceuticals, Inc. SEC filings · US GAAP · Rhythm Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026